Study guide
39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS
Philippine Physician Licensure Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: PLE Structure, Eligibility & Study Strategy
1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan
2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle
2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction
3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems
3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments
4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems
4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation
5 Chapter 5: Physiology IV: Neurophysiology & Special Senses
5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses
6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death
6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death
7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning
7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws
8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics
8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics
9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics
9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock
10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection
10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology
11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology
11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura
12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology
12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors
13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry
13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism
14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry
14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure
15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back
15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes
16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin
16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands
17 Chapter 17: Anatomy III: Head, Neck & Histology
17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology
18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections
18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis
19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections
19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning
20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections
20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases
21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections
21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis
22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding
22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage
23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems
23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception
24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception
24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria
25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues
25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents
26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections
26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections
27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders
27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning
28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders
28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child
29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider
29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036
30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine
30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine
31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer
31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health
32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics
32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections
33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics
33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy
34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics
34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis
35 Chapter 35: Surgery I: Basic Surgical Principles
35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety
36 Chapter 36: Surgery II: Abdomen, Breast & Hernia
36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma
37 Chapter 37: Surgery III: Surgical Specialties
37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)
38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine
38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome
39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine
39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS
40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry
40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)
39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS
Key Takeaways Explain This Topic AI
Type 1 respiratory failure is hypoxemia (PaO2 below 60 mmHg) with normal or low PaCO2; type 2 is hypercapnia (PaCO2 above 45 to 50 mmHg) from hypoventilation.
Target SpO2 of 88% to 92% in patients at risk of hypercapnia such as COPD, and 92% to 96% in most other acutely ill adults.
Non-invasive ventilation is first-line for a COPD exacerbation with respiratory acidosis (pH below 7.35 and PaCO2 above 45 mmHg).
Drug-susceptible TB is treated with 2HRZE/4HR; rifampicin-resistant TB detected by Xpert is referred for an all-oral regimen such as the 6-month BPaLM.
Lung adenocarcinoma is the most common lung cancer and often carries EGFR mutations in Asian never-smokers; small cell lung cancer causes SIADH and Lambert-Eaton syndrome.
Last updated: October 2026
Why this area matters
The Philippines has one of the highest TB burdens in the world , and pneumonia is among the leading causes of death. COPD from smoking and biomass smoke, asthma and lung cancer (a leading cause of cancer death in Filipino men) are frequent. The PLE asks for oxygen targets, ventilation choices, antibiotic regimens by risk class, and TB program rules.
Acute respiratory failure
Type 1 (hypoxemic): PaO2 below 60 mmHg with normal or low PaCO2, from V/Q mismatch (pneumonia, PE, asthma), shunt (ARDS, atelectasis, edema) or diffusion problems. The A-a gradient is raised .
Type 2 (hypercapnic): PaCO2 above 45 to 50 mmHg from hypoventilation : COPD and asthma exhaustion, drug overdose (opioids, sedatives), neuromuscular disease (Guillain-Barré, myasthenia, snakebite neurotoxicity), chest wall disease and obesity hypoventilation. The A-a gradient is normal in pure hypoventilation.
Oxygen targets:
SpO2 92% to 96% for most acutely ill adults (avoid hyperoxia);
88% to 92% for those at risk of hypercapnia (COPD, obesity hypoventilation, neuromuscular disease), using controlled oxygen (Venturi mask).
Support:
- high-flow nasal cannula for hypoxemic failure;
- non-invasive ventilation (BiPAP) for hypercapnic COPD exacerbations and cardiogenic pulmonary edema;
intubation for failure of non-invasive support, coma, inability to protect the airway, or shock.
Massive hemoptysis: protect the airway, lie the patient bleeding side down , and arrange bronchial artery embolization . TB, bronchiectasis and lung cancer are the common causes.
Bronchial Asthma
Bronchial asthma is a heterogeneous chronic airway disease characterized by chronic airway inflammation, bronchial hyperresponsiveness, and variable, reversible expiratory airflow limitation.
Diagnostic Hallmarks & Spirometry
Variable Airflow Limitation: Spirometry remains the diagnostic cornerstone. A positive bronchodilator reversibility test is defined as an increase in FEV 1 \text{FEV}_1 FEV 1 of > 12 % > 12\% > 12% and > 200 mL > 200\text{ mL} > 200 mL compared to baseline, 10 to 15 minutes after inhaling 200 − 400 μ g 200-400\text{ }\mu\text{g} 200 − 400 μ g of salbutamol/albuterol.
Peak Expiratory Flow (PEF) Variability: Excessive diurnal variation in PEF ( > 10 % > 10\% > 10% in adults based on twice-daily readings over 1 to 2 weeks).
Bronchial Provocation Testing: When baseline spirometry is normal, bronchoprovocation with inhaled methacholine or histamine demonstrating a PC 20 \text{PC}_{20} PC 20 (provocative concentration causing a 20 % 20\% 20% fall in FEV 1 \text{FEV}_1 FEV 1 ) ≤ 8 mg/mL \le 8\text{ mg/mL} ≤ 8 mg/mL establishes hyperresponsiveness.
Global Initiative for Asthma (GINA) Management Framework
GINA fundamentally transformed asthma care by eliminating short-acting beta-2 agonist (SABA) monotherapy due to increased risks of fatal exacerbations:
Track 1 (Preferred Strategy): Low-dose inhaled corticosteroid (ICS)-formoterol used as both daily maintenance (or PRN in mild disease) and the as-needed reliever across all steps (Steps 1 to 5). Formoterol provides rapid-onset bronchodilation comparable to salbutamol within 1 to 3 minutes while delivering a concomitant anti-inflammatory dose of ICS.
Track 2 (Alternative Strategy): Maintenance ICS plus as-needed SABA reliever. Daily adherence to ICS is strictly required before prescribing SABA.
Stepwise Titration:
Steps 1-2: As-needed low-dose ICS-formoterol alone.
Step 3: Low-dose maintenance ICS-formoterol + as-needed reliever.
Step 4: Medium-dose maintenance ICS-formoterol + as-needed reliever.
Step 5: High-dose maintenance ICS-formoterol, add-on long-acting muscarinic antagonist (LAMA, tiotropium), and targeted biologics (e.g., Omalizumab for anti-IgE; Mepolizumab, Benralizumab for eosinophilic asthma targeting IL-5; Dupilumab targeting IL-4/IL-13).
Acute Severe Asthma (Status Asthmaticus)
An acute exacerbation unresponsive to standard outpatient bronchodilators, presenting with tachypnea, pulsus paradoxus, intercostal retractions, and diaphoresis.
Life-Threatening Signs: "Silent chest" (absence of wheezing due to severe airflow limitation), cyanosis, bradycardia, confusion, exhaustion, and pseudonormal or elevated PaCO 2 \text{PaCO}_2 PaCO 2 ( > 42 mmHg > 42\text{ mmHg} > 42 mmHg ) . In a hyperventilating asthmatic, PaCO 2 \text{PaCO}_2 PaCO 2 should be low; a normal or rising PaCO 2 \text{PaCO}_2 PaCO 2 heralds impending respiratory arrest.
Emergency Management:
Supplemental oxygen to maintain SpO 2 \text{SpO}_2 SpO 2 93% to 95%.
Repetitive or continuous nebulized SABA (salbutamol 2.5 − 5.0 mg 2.5-5.0\text{ mg} 2.5 − 5.0 mg ) combined with inhaled ipratropium bromide ( 0.5 mg 0.5\text{ mg} 0.5 mg ) every 20 minutes for the first hour.
Early systemic corticosteroids: oral prednisone 40 − 50 mg 40-50\text{ mg} 40 − 50 mg or intravenous hydrocortisone 100 − 200 mg 100-200\text{ mg} 100 − 200 mg / methylprednisolone 60 − 80 mg 60-80\text{ mg} 60 − 80 mg .
Intravenous Magnesium Sulfate ( 2 g 2\text{ g} 2 g over 20 minutes) for severe refractory exacerbations.
Mechanical ventilation: Avoid hyperventilation; tolerate permissive hypercapnia; maintain low respiratory rates and prolonged expiratory times ( I : E I:E I : E ratio 1 : 3 1:3 1 : 3 to 1 : 4 1:4 1 : 4 ) to prevent dynamic hyperinflation (auto-PEEP) and tension pneumothorax.
Chronic Obstructive Pulmonary Disease (COPD)
COPD is characterized by persistent, progressive airflow limitation resulting from chronic inflammatory responses in airways and lung parenchyma to noxious particles, primarily cigarette smoke and biomass fuel exposure.
Diagnostic Criteria & GOLD Classification
Diagnostic Hallmark: A post-bronchodilator FEV 1 / FVC < 0.70 \text{FEV}_1/\text{FVC} < 0.70 FEV 1 / FVC < 0.70 establishes persistent, non-fully reversible airflow obstruction.
GOLD Spirometric Grades (based on post-bronchodilator FEV 1 % \text{FEV}_1\% FEV 1 % predicted):
GOLD 1 (Mild): FEV 1 ≥ 80 % \text{FEV}_1 \ge 80\% FEV 1 ≥ 80% predicted.
GOLD 2 (Moderate): 50 % ≤ FEV 1 < 80 % 50\% \le \text{FEV}_1 < 80\% 50% ≤ FEV 1 < 80% predicted.
GOLD 3 (Severe): 30 % ≤ FEV 1 < 50 % 30\% \le \text{FEV}_1 < 50\% 30% ≤ FEV 1 < 50% predicted.
GOLD 4 (Very Severe): FEV 1 < 30 % \text{FEV}_1 < 30\% FEV 1 < 30% predicted.
Pharmacologic Maintenance (GOLD ABE Schema)
Initial Maintenance: Inhaled long-acting muscarinic antagonists (LAMA: tiotropium) and/or long-acting beta-2 agonists (LABA: indacaterol, formoterol). Group A starts with a single bronchodilator; LAMA + LABA combination is first-line for Group B (more symptoms) and Group E (exacerbations).
Inhaled Corticosteroids (ICS): Reserved as add-on therapy (triple therapy: LAMA + LABA + ICS) in patients with frequent exacerbations ( ≥ 2 \ge 2 ≥ 2 per year or ≥ 1 \ge 1 ≥ 1 leading to hospitalization) AND blood eosinophil counts ≥ 300 cells/ μ L \ge 300\text{ cells/}\mu\text{L} ≥ 300 cells/ μ L (or ≥ 100 cells/ μ L \ge 100\text{ cells/}\mu\text{L} ≥ 100 cells/ μ L with repeated exacerbations). ICS is avoided when repeated pneumonia episodes occur.
Interventions Proven to Reduce Mortality in COPD:
Smoking Cessation: The single most effective intervention to halt accelerated decline in FEV 1 \text{FEV}_1 FEV 1 .
Long-Term Oxygen Therapy (LTOT): Administered ≥ 15 hours/day \ge 15\text{ hours/day} ≥ 15 hours/day for resting chronic hypoxemia ( PaO 2 ≤ 55 mmHg \text{PaO}_2 \le 55\text{ mmHg} PaO 2 ≤ 55 mmHg or SpO 2 ≤ 88 % \text{SpO}_2 \le 88\% SpO 2 ≤ 88% , or PaO 2 56 − 59 mmHg \text{PaO}_2 56-59\text{ mmHg} PaO 2 56 − 59 mmHg if cor pulmonale, right heart failure, or secondary polycythemia is present).
Lung Volume Reduction Surgery (LVRS): In highly selected patients with severe upper-lobe emphysema and low exercise capacity.
Acute Exacerbations of COPD (AECOPD)
Anthonisen Criteria for Antibiotic Use:
Increasing dyspnea.
Increasing sputum volume.
Increasing sputum purulence. Recommendation: Antibiotics are indicated if all three cardinal symptoms are present (Type 1), or if increased purulence is present plus one other symptom (Type 2). Common regimens: Amoxicillin-clavulanate, azithromycin, or respiratory fluoroquinolones for 5 to 7 days.
Systemic Corticosteroids: Oral prednisone 40 mg 40\text{ mg} 40 mg once daily for 5 days accelerates recovery and prevents relapse.
Non-Invasive Positive Pressure Ventilation (NIPV / BiPAP): The primary ventilatory modality of choice for acute hypercapnic respiratory acidosis ( pH < 7.35 \text{pH} < 7.35 pH < 7.35 and PaCO 2 > 45 mmHg \text{PaCO}_2 > 45\text{ mmHg} PaCO 2 > 45 mmHg ). NIPV reduces intubation rates, hospital stay, and in-hospital mortality.
Community-Acquired Pneumonia (CAP)
Community-acquired pneumonia is an acute infectious inflammation of the lower respiratory tract in non-hospitalized individuals.
Clinical Risk Stratification: CURB-65 & Philippine CPG Guidelines
Assessment Tool Scoring Components Stratification & Recommended Management
CURB-65 Score C : Confusion (abbreviated mental test ≤ 8 \le 8 ≤ 8 ); U : Urea > 7 mmol/L > 7\text{ mmol/L} > 7 mmol/L (BUN > 19 mg/dL > 19\text{ mg/dL} > 19 mg/dL ); R : Respiratory rate ≥ 30 breaths/min \ge 30\text{ breaths/min} ≥ 30 breaths/min ; B : Blood pressure ( S B P < 90 SBP < 90 SBP < 90 or D B P ≤ 60 mmHg DBP \le 60\text{ mmHg} D BP ≤ 60 mmHg ); 65 : Age ≥ 65 \ge 65 ≥ 65 years Score 0-1: Low risk (mortality < 2 − 3 % < 2-3\% < 2 − 3% , outpatient care); Score 2: Intermediate risk (short inpatient stay or close outpatient care); Score 3-5: High risk (mortality 15 − 30 % 15-30\% 15 − 30% , urgent hospital admission, consider ICU for score ≥ 4 \ge 4 ≥ 4 )
Philippine CPG on CAP Evaluates hemodynamic stability, vital signs, comorbid diseases, and chest radiograph extent Low-Risk CAP: Outpatient oral therapy; Moderate-Risk CAP: Inpatient ward intravenous therapy; High-Risk CAP: Immediate ICU admission
Empiric Antimicrobial Regimens
Outpatient Low-Risk CAP (Healthy, No Comorbidities): High-dose oral Amoxicillin ( 1 g 1\text{ g} 1 g TID) or Azithromycin ( 500 mg 500\text{ mg} 500 mg Day 1, then 250 mg 250\text{ mg} 250 mg Days 2-5) or Doxycycline ( 100 mg 100\text{ mg} 100 mg BID).
Outpatient with Comorbidities / Moderate Risk: Oral Amoxicillin-clavulanate ( 875 / 125 mg 875/125\text{ mg} 875/125 mg BID) or Cefuroxime axetil PLUS a macrolide (Azithromycin), OR respiratory fluoroquinolone monotherapy (Levofloxacin 750 mg 750\text{ mg} 750 mg or Moxifloxacin 400 mg 400\text{ mg} 400 mg daily).
Inpatient Non-Severe (Hospital Ward): Intravenous beta-lactam (Ceftriaxone 1 − 2 g 1-2\text{ g} 1 − 2 g IV daily, Ampicillin-sulbactam 1.5 − 3.0 g 1.5-3.0\text{ g} 1.5 − 3.0 g IV q6h) PLUS intravenous/oral Azithromycin, OR respiratory fluoroquinolone monotherapy.
Inpatient Severe (ICU): Intravenous non-antipseudomonal beta-lactam (Ceftriaxone or Ampicillin-sulbactam) PLUS intravenous Azithromycin or a respiratory fluoroquinolone. Use an antipseudomonal beta-lactam (Piperacillin-tazobactam 4.5 g 4.5\text{ g} 4.5 g IV q6h, Cefepime 2 g 2\text{ g} 2 g IV q8h, or Meropenem 1 g 1\text{ g} 1 g IV q8h) only when risk factors for Pseudomonas are present (structural lung disease such as bronchiectasis, recent hospitalization with IV antibiotics, or prior isolation), and add Vancomycin or Linezolid if MRSA is suspected.
Pulmonary Tuberculosis & Philippine National TB Control Program (NTP)
The Philippines remains an endemic country for tuberculosis, necessitating standardized programmatic diagnostic pathways and directly observed therapy.
Diagnostic Strategy & Molecular GeneXpert MTB/RIF
Presumptive TB Definition: Any individual presenting with cough lasting ≥ 2 weeks \ge 2\text{ weeks} ≥ 2 weeks , unexplained fever, night sweats, significant weight loss, hemoptysis, or suspicious chest radiograph lesions.
Primary Diagnostic Tool: GeneXpert MTB/RIF (or Ultra) is the mandatory initial diagnostic test for all presumptive pulmonary and extrapulmonary TB cases. It utilizes automated real-time PCR to detect Mycobacterium tuberculosis complex DNA and simultaneously identifies mutations in the rpoB gene conferring rifampicin resistance within 2 hours.
Chest Radiography (CXR): Primary screening examination; reactivation TB classically demonstrates apical and posterior segment infiltrates of upper lobes, with or without cavitation.
Sputum Smear Microscopy (DSSM): Used primarily for monitoring treatment response in bacteriologically confirmed pulmonary TB: at the end of the intensive phase (month 2), at month 5, and at the end of treatment (month 6).
Standard NTP Treatment Regimens & Drug Mechanisms
Regimen 1 (Drug-Susceptible Pulmonary and Most Extrapulmonary TB; formerly "Category I"):
Intensive Phase (2 Months): 2HRZE — Daily Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), and Ethambutol (E) in Fixed-Dose Combinations (FDC).
Continuation Phase (4 Months): 4HR — Daily Isoniazid and Rifampicin.
Regimen 2 (TB Meningitis and Bone or Joint TB): 2HRZE/10HR, extending the continuation phase to 10 months.
First-Line Antituberculosis Agent Mechanism of Action Classic Adverse Drug Reactions & Monitoring Protocols
Isoniazid (H) Inhibits mycolic acid synthesis in mycobacterial cell wall Peripheral neuropathy (due to pyridoxine/vitamin B 6 B_6 B 6 depletion; co-prescribe pyridoxine 25 − 50 mg 25-50\text{ mg} 25 − 50 mg daily); drug-induced hepatotoxicity; drug-induced lupus erythematosus
Rifampicin (R) Inhibits DNA-dependent RNA polymerase Benign orange-red discoloration of body fluids (urine, tears, sweat; patient education crucial); potent cytochrome P450 inducer (lowers levels of oral contraceptives, warfarin, antiretrovirals, calcium channel blockers); hepatitis; thrombocytopenia
Pyrazinamide (Z) Disrupted membrane potential and energy transport in acidic phagolysosomes Hyperuricemia (often asymptomatic, but may precipitate acute gouty arthritis); most hepatotoxic of first-line agents; polyarthralgias
Ethambutol (E) Inhibits arabinosyl transferase , blocking arabinogalactan synthesis Retrobulbar optic neuritis (decreased visual acuity, central scotoma, loss of red-green color discrimination ); baseline and periodic visual acuity/Ishihara color plate testing; at 15 to 25 mg/kg it is considered safe in children (WHO), with care in young children who cannot report visual changes
Drug-Induced Liver Injury (DILI) Protocol: Discontinue all hepatotoxic agents (H, R, Z) immediately if serum ALT/AST rises > 3 > 3 > 3 times upper limit of normal with jaundice/hepatitis symptoms, or > 5 > 5 > 5 times upper limit of normal without symptoms. Once enzymes normalize, rechallenge sequentially.
Acute Respiratory Distress Syndrome (ARDS) & Critical Care
ARDS is acute, diffuse, inflammatory alveolar injury leading to increased vascular permeability, loss of aerated lung tissue, and refractory hypoxemia.
The Berlin Definition of ARDS
Timing: Within 1 week of a known clinical insult (sepsis, severe pneumonia, aspiration, pancreatitis, massive trauma) or new/worsening respiratory symptoms.
Chest Imaging: Bilateral pulmonary opacities not fully explained by pleural effusions, lobar collapse, or nodules.
Origin of Edema: Respiratory failure not fully explained by cardiac failure or hydrostatic volume overload; objective assessment (echocardiography) required to exclude cardiogenic pulmonary edema.
Oxygenation Impairment (measured with PEEP ≥ 5 cm H 2 O \text{PEEP} \ge 5\text{ cm H}_2\text{O} PEEP ≥ 5 cm H 2 O ):
Mild ARDS: 200 < PaO 2 / FiO 2 ≤ 300 mmHg 200 < \text{PaO}_2/\text{FiO}_2 \le 300\text{ mmHg} 200 < PaO 2 / FiO 2 ≤ 300 mmHg .
Moderate ARDS: 100 < PaO 2 / FiO 2 ≤ 200 mmHg 100 < \text{PaO}_2/\text{FiO}_2 \le 200\text{ mmHg} 100 < PaO 2 / FiO 2 ≤ 200 mmHg .
Severe ARDS: PaO 2 / FiO 2 ≤ 100 mmHg \text{PaO}_2/\text{FiO}_2 \le 100\text{ mmHg} PaO 2 / FiO 2 ≤ 100 mmHg .
Evidence-Based Lung-Protective Mechanical Ventilation
Low Tidal Volume Ventilation: Ventilate with a tidal volume of 4 to 8 mL/kg 4\text{ to }8\text{ mL/kg} 4 to 8 mL/kg of Predicted Body Weight (PBW) , starting at 6 mL/kg PBW 6\text{ mL/kg PBW} 6 mL/kg PBW (PBW is calculated from height and sex, NOT actual total body weight). This prevents ventilator-induced lung injury (volutrauma).
Plateau Pressure Limitation: Maintain inspiratory end-inspiratory plateau airway pressure ( P p l a t P_{plat} P pl a t ) ≤ 30 cm H 2 O \le 30\text{ cm H}_2\text{O} ≤ 30 cm H 2 O to prevent barotrauma.
Permissive Hypercapnia: Allow moderate arterial respiratory acidosis ( pH ≥ 7.20 − 7.25 \text{pH} \ge 7.20-7.25 pH ≥ 7.20 − 7.25 ) to maintain low tidal volumes, provided cerebral perfusion is uncompromised.
Prone Positioning: Strongly recommended for ≥ 16 consecutive hours per day \ge 16\text{ consecutive hours per day} ≥ 16 consecutive hours per day in patients with moderate-to-severe ARDS ( PaO 2 / FiO 2 < 150 mmHg \text{PaO}_2/\text{FiO}_2 < 150\text{ mmHg} PaO 2 / FiO 2 < 150 mmHg ). Prone ventilation optimizes dorsal alveolar recruitment, balances ventilation-perfusion matching, and significantly reduces 28-day mortality.
More on pneumonia
Diagnosis: new infiltrate on chest X-ray with symptoms. Sputum Gram stain and culture and blood cultures for admitted patients, plus TB testing when the course is subacute.
Hospital-acquired and ventilator-associated pneumonia (48 hours or more after admission or intubation): cover Pseudomonas , Klebsiella , Acinetobacter and MRSA based on local data.
Aspiration pneumonia: stroke, alcohol, seizures and dysphagia. Affects dependent segments (right lower lobe; posterior upper lobe when supine). Lung abscess follows.
Viral pneumonia: influenza, COVID-19 and RSV. Oseltamivir within 48 hours (or any time in hospitalized and high-risk patients). Watch for secondary S. aureus pneumonia after influenza.
Melioidosis ( Burkholderia pseudomallei ): in diabetics after soil and water exposure; pneumonia, abscesses and sepsis, treated with ceftazidime or meropenem.
Prevention: pneumococcal and influenza vaccination for the elderly and those with chronic disease, and stopping smoking.
More on tuberculosis
Drug-resistant TB:
suspect it after treatment failure, relapse, contact with MDR-TB or rifampicin resistance on Xpert;
treated by PMDT facilities with all-oral regimens such as BPaLM (bedaquiline, pretomanid, linezolid, moxifloxacin) for 6 months (WHO 2022), with ECG monitoring for QT prolongation and watching for linezolid neuropathy and myelosuppression .
Extrapulmonary TB:
- TB lymphadenitis : the most common form; matted cervical nodes and scrofula;
- pleural TB : lymphocytic exudate with high ADA ;
TB meningitis and spinal TB : longer treatment (2HRZE/10HR) with steroids for meningitis.
TB and HIV: offer HIV testing to all TB patients, and start ART within 2 weeks of TB treatment.
TB infection (latent TB) and TB preventive treatment:
detected by tuberculin skin test or IGRA , after excluding active disease;
TB preventive treatment for household contacts (especially children under 5), people living with HIV , and patients starting biologics or dialysis;
regimens: 3HP (weekly isoniazid-rifapentine for 3 months), 3HR, or 6H (6 months of isoniazid).
Case finding: chest X-ray screening and Xpert testing for presumptive TB; treatment support (directly observed or digital) to ensure adherence.
Pulmonary embolism
Risk factors: recent surgery, immobilization, cancer, pregnancy and estrogen, prior VTE and thrombophilia.
Presentation: sudden dyspnea, pleuritic chest pain, tachycardia, hypoxia, hemoptysis and syncope. ECG may show sinus tachycardia or the S1Q3T3 pattern (uncommon).
Diagnosis:
- Wells score ;
- D-dimer to rule out PE when pretest probability is low;
CT pulmonary angiography (V/Q scan in pregnancy or contrast allergy).
Treatment:
- anticoagulation with a DOAC or low molecular weight heparin, for at least 3 months;
- systemic thrombolysis for massive PE with hypotension ;
an IVC filter only if anticoagulation is contraindicated.
Lung cancer
Risk factors: smoking (including secondhand), radon, asbestos, biomass smoke and air pollution.
Types:
adenocarcinoma : the most common type; peripheral; also seen in never-smokers, especially Asian women , often with EGFR mutations treated with oral tyrosine kinase inhibitors (osimertinib);
squamous cell carcinoma : central, cavitating, linked to smoking, with hypercalcemia from PTHrP;
small cell carcinoma : central, aggressive, early spread, linked to SIADH , ectopic ACTH and Lambert-Eaton syndrome ; treated with chemotherapy, radiotherapy and immunotherapy.
Presentation: cough, hemoptysis, weight loss, post-obstructive pneumonia, superior vena cava syndrome (facial swelling, dilated chest veins), Pancoast tumor with Horner syndrome, hoarseness (recurrent laryngeal nerve) and clubbing .
Workup:
- CT chest and abdomen;
- tissue diagnosis by bronchoscopy, CT-guided biopsy or EBUS;
- molecular testing of adenocarcinoma (EGFR, ALK, PD-L1);
staging with PET-CT and brain MRI.
Screening: low-dose CT yearly for adults aged 50 to 80 with a 20 pack-year smoking history who smoke now or quit within 15 years (USPSTF 2021).
Prevention: tobacco control (the Graphic Health Warnings Act, sin taxes, smoke-free laws) and cessation support.